Skip to main content

Chase Doyle

Authored Items
Rapid Biosimilar Adoption Possible in Community Oncology Practice
Chase Doyle
Web Exclusives in Biosimilars, ASCO Highlights
Delivering High-Value Personalized Interventions
Chase Doyle
Web Exclusives in Clinical Trials
Patients with Medicaid or No Insurance Have Worse Survival in Clinical Trials
Chase Doyle
Web Exclusives in Clinical Trials
Oral Parity Laws Could Reduce Disparities in Cancer Care
Chase Doyle
Web Exclusives in Disparities in Oncology Care
Patient-Centered Clinical Pathways Should Incorporate the Patient’s Voice
Chase Doyle
Web Exclusives in Clinical Trials
Financial Toxicity High for Low-Income Patients in Early-Phase Clinical Trials
Chase Doyle
Web Exclusives
Avelumab plus Axitinib New First-Line Standard of Care in Advanced Renal-Cell Carcinoma
Chase Doyle
Web Exclusives in Renal-Cell Carcinoma
Economic Implications of Inpatient versus Outpatient Autologous Transplant for Patients with Multiple Myeloma
Chase Doyle
Web Exclusives in Multiple Myeloma
CAR T-Cell Therapy Targeting Solid Tumors
Chase Doyle
Web Exclusives in Immunotherapy
CAR T-Cell Therapy Yields Impressive Responses in Aggressive Blood Cancer
Chase Doyle
Web Exclusives in Immunotherapy
First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer
Chase Doyle
Web Exclusives in Breast Cancer
New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs
Chase Doyle
Web Exclusives
Programs Raise Awareness of Risks Associated with Testosterone Replacement Therapy
Chase Doyle
Web Exclusives in Genitourinary Cancers
Last modified: December 11, 2015